BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 25605014)

  • 1. Top2a identifies and provides epigenetic rationale for novel combination therapeutic strategies for aggressive prostate cancer.
    Kirk JS; Schaarschuch K; Dalimov Z; Lasorsa E; Ku S; Ramakrishnan S; Hu Q; Azabdaftari G; Wang J; Pili R; Ellis L
    Oncotarget; 2015 Feb; 6(5):3136-46. PubMed ID: 25605014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TOP2A and EZH2 Provide Early Detection of an Aggressive Prostate Cancer Subgroup.
    Labbé DP; Sweeney CJ; Brown M; Galbo P; Rosario S; Wadosky KM; Ku SY; Sjöström M; Alshalalfa M; Erho N; Davicioni E; Karnes RJ; Schaeffer EM; Jenkins RB; Den RB; Ross AE; Bowden M; Huang Y; Gray KP; Feng FY; Spratt DE; Goodrich DW; Eng KH; Ellis L
    Clin Cancer Res; 2017 Nov; 23(22):7072-7083. PubMed ID: 28899973
    [No Abstract]   [Full Text] [Related]  

  • 3. Expression and inhibition of BRD4, EZH2 and TOP2A in neurofibromas and malignant peripheral nerve sheath tumors.
    Amirnasr A; Verdijk RM; van Kuijk PF; Taal W; Sleijfer S; Wiemer EAC
    PLoS One; 2017; 12(8):e0183155. PubMed ID: 28813519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA topoisomerase IIalpha (TOP2A) inhibitors up-regulate fatty acid synthase gene expression in SK-Br3 breast cancer cells: in vitro evidence for a 'functional amplicon' involving FAS, Her-2/neu and TOP2A genes.
    Menendez JA; Vellon L; Lupu R
    Int J Mol Med; 2006 Dec; 18(6):1081-7. PubMed ID: 17089011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ataxia telangiectasia mutated-dependent regulation of topoisomerase II alpha expression and sensitivity to topoisomerase II inhibitor.
    Tamaichi H; Sato M; Porter AC; Shimizu T; Mizutani S; Takagi M
    Cancer Sci; 2013 Feb; 104(2):178-84. PubMed ID: 23163762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The value of TOP2A, EZH2 and paxillin expression as markers of aggressive breast cancer: relationship with other prognostic factors.
    Panousis D; Patsouris E; Lagoudianakis E; Pappas A; Kyriakidou V; Voulgaris Z; Xepapadakis G; Manouras A; Athanassiadou AM; Athanassiadou P
    Eur J Gynaecol Oncol; 2011; 32(2):156-9. PubMed ID: 21614903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TOP2A is overexpressed and is a therapeutic target for adrenocortical carcinoma.
    Jain M; Zhang L; He M; Zhang YQ; Shen M; Kebebew E
    Endocr Relat Cancer; 2013 Jun; 20(3):361-70. PubMed ID: 23533247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostication of prostate cancer based on TOP2A protein and gene assessment: TOP2A in prostate cancer.
    de Resende MF; Vieira S; Chinen LT; Chiappelli F; da Fonseca FP; Guimarães GC; Soares FA; Neves I; Pagotty S; Pellionisz PA; Barkhordarian A; Brant X; Rocha RM
    J Transl Med; 2013 Feb; 11():36. PubMed ID: 23398928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual Inhibition of EZH2 and EZH1 Sensitizes PRC2-Dependent Tumors to Proteasome Inhibition.
    Rizq O; Mimura N; Oshima M; Saraya A; Koide S; Kato Y; Aoyama K; Nakajima-Takagi Y; Wang C; Chiba T; Ma A; Jin J; Iseki T; Nakaseko C; Iwama A
    Clin Cancer Res; 2017 Aug; 23(16):4817-4830. PubMed ID: 28490465
    [No Abstract]   [Full Text] [Related]  

  • 10. Simultaneous amplification of HER-2 (ERBB2) and topoisomerase IIalpha (TOP2A) genes--molecular basis for combination chemotherapy in cancer.
    Järvinen TA; Liu ET
    Curr Cancer Drug Targets; 2006 Nov; 6(7):579-602. PubMed ID: 17100565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual functions of the homeoprotein DLX4 in modulating responsiveness of tumor cells to topoisomerase II-targeting drugs.
    Trinh BQ; Ko SY; Barengo N; Lin SY; Naora H
    Cancer Res; 2013 Jan; 73(2):1000-10. PubMed ID: 23222298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of O⁶-methylguanine-DNA methyltransferase confers collateral sensitivity to carmustine in topoisomerase II-mediated doxorubicin resistant triple negative breast cancer cells.
    Raguz S; Adams C; Masrour N; Rasul S; Papoutsoglou P; Hu Y; Cazzanelli G; Zhou Y; Patel N; Coombes C; Yagüe E
    Biochem Pharmacol; 2013 Jan; 85(2):186-96. PubMed ID: 23122841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Higher topoisomerase 2 alpha gene transcript levels predict better prognosis in GBM patients receiving temozolomide chemotherapy: identification of temozolomide as a TOP2A inhibitor.
    Arivazhagan A; Kumar DM; Sagar V; Patric IR; Sridevi S; Thota B; Srividya MR; Prasanna K; Thennarasu K; Mondal N; Hegde AS; Chandramouli BA; Santosh V; Rao MR; Kondaiah P; Somasundaram K
    J Neurooncol; 2012 Apr; 107(2):289-97. PubMed ID: 22102081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of the antiproliferative effects of 3-deazaneoplanocin A in combination with standard anticancer agents in rhabdoid tumor cell lines.
    Unland R; Borchardt C; Clemens D; Kool M; Dirksen U; Frühwald MC
    Anticancer Drugs; 2015 Mar; 26(3):301-11. PubMed ID: 25415657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of coexistence of DNA methylation and H3K27me3 specifically in cancer cells as a promising target for epigenetic therapy.
    Takeshima H; Wakabayashi M; Hattori N; Yamashita S; Ushijima T
    Carcinogenesis; 2015 Feb; 36(2):192-201. PubMed ID: 25477340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical validation of overexpressed genes identified by global expression microarrays in adrenocortical carcinoma reveals potential predictive and prognostic biomarkers.
    Ip JC; Pang TC; Glover AR; Soon P; Zhao JT; Clarke S; Robinson BG; Gill AJ; Sidhu SB
    Oncologist; 2015 Mar; 20(3):247-56. PubMed ID: 25657202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of EZH2 by chemo- and radiotherapy agents and small molecule inhibitors induces cell death in castration-resistant prostate cancer.
    Wu C; Jin X; Yang J; Yang Y; He Y; Ding L; Pan Y; Chen S; Jiang J; Huang H
    Oncotarget; 2016 Jan; 7(3):3440-52. PubMed ID: 26657505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MiR-23a-mediated inhibition of topoisomerase 1 expression potentiates cell response to etoposide in human hepatocellular carcinoma.
    Wang N; Zhu M; Tsao SW; Man K; Zhang Z; Feng Y
    Mol Cancer; 2013 Oct; 12(1):119. PubMed ID: 24103454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ethonafide-induced cytotoxicity is mediated by topoisomerase II inhibition in prostate cancer cells.
    Pourpak A; Landowski TH; Dorr RT
    J Pharmacol Exp Ther; 2007 Jun; 321(3):1109-17. PubMed ID: 17351106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EZH2, an epigenetic driver of prostate cancer.
    Yang YA; Yu J
    Protein Cell; 2013 May; 4(5):331-41. PubMed ID: 23636686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.